{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:47:22Z","timestamp":1776746842517,"version":"3.51.2"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Swedish Veterinary Care Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Canine Genet Epidemiol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In people, bile acid diarrhoea is a prevalent complication of Crohn\u2019s disease and diarrhoea-associated irritable bowel syndrome. Affected patients typically respond to bile acid sequestrants, such as cholestyramine, but human gastroenterologists often fail to recognize bile acid diarrhoea. Consequently, bile acid diarrhoea is regarded as an underrecognized and undertreated condition in human medicine. Due to lack of diagnostic tools, clinical response to bile acid sequestrants is often used to confirm a diagnosis of bile acid diarrhoea in people.<\/jats:p>\n                <jats:p>Several recent studies have shown that bile acid dysmetabolism also occurs in dogs with chronic enteropathies. It has further been shown that dogs with chronic enteropathies have significantly decreased expression of a bile acid transport protein in the ileum compared to healthy dogs, which correlates with faecal bile acid dysmetabolism. Consequently, in spite of the lack of reports in the literature, bile acid diarrhoea is likely to exist in dogs as well.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case descriptions<\/jats:title>\n                <jats:p>Two dogs, an 8-year old Rottweiler and a 4.5-year old Siberian Husky were evaluated for chronic watery diarrhoea. Neither dog responded to dietary trials, probiotics, cyclosporine, faecal microbial transplantations or metronidazole. One of the dogs responded to high daily doses of corticosteroids, which were however associated with unacceptable side effects. The other dog was refractory to all standard treatment protocols, including cyclosporine and corticosteroids. Since none of the dogs responded satisfactorily to standard treatment or modulation of the intestinal microbiome, a suspicion of possible bile acid diarrhoea was raised. Treatment with cholestyramine, a bile acid sequestrant was initiated and resulted in marked improvement of faecal consistency, frequency of defecation and activity level in both dogs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This report presents two dogs with presumed bile acid diarrhoea that were successfully treated with cholestyramine. Therefore, bile acid diarrhoea should be considered as a possible diagnosis in dogs with treatment-refractory chronic diarrhoea.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40575-021-00099-x","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T09:02:51Z","timestamp":1611046971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cholestyramine treatment in two dogs with presumptive bile acid diarrhoea: a case report"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2003-9554","authenticated-orcid":false,"given":"L.","family":"Toresson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. S.","family":"Suchodolski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"issue":"4","key":"99_CR1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0016-5085(67)80140-9","volume":"52","author":"AF Hofmann","year":"1967","unstructured":"Hofmann AF. The syndrome of ileal disease and the broken enterohepatic circulation: cholerheic enteropathy. Gastroenterology. 1967;52(4):752\u20137.","journal-title":"Gastroenterology."},{"issue":"Pt 1","key":"99_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1099\/00207713-51-1-39","volume":"51","author":"M Kitahara","year":"2001","unstructured":"Kitahara M, Takamine F, Imamura T, Benno Y. Clostridium hiranonis sp. nov., a human intestinal bacterium with bile acid 7alpha-dehydroxylating activity. Int J Syst Evol Microbiol. 2001;51(Pt 1):39\u201344.","journal-title":"Int J Syst Evol Microbiol"},{"issue":"3","key":"99_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.5009\/gnl14397","volume":"9","author":"M Camilleri","year":"2015","unstructured":"Camilleri M. Bile acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver. 2015;9(3):332\u20139.","journal-title":"Gut Liver"},{"issue":"6","key":"99_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/1756283X10377126","volume":"3","author":"JR Walters","year":"2010","unstructured":"Walters JR, Pattni SS. Managing bile acid diarrhoea. Ther Adv Gastroenterol. 2010;3(6):349\u201357.","journal-title":"Ther Adv Gastroenterol"},{"issue":"2","key":"99_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.7861\/clinmedicine.10-2-124","volume":"10","author":"U Khalid","year":"2010","unstructured":"Khalid U, Lalji A, Stafferton R, Andreyev J. Bile acid malabsoption: a forgotten diagnosis? Clin Med (Lond). 2010;10(2):124\u20136.","journal-title":"Clin Med (Lond)"},{"issue":"4","key":"99_CR6","doi-asserted-by":"publisher","first-page":"S715","DOI":"10.1016\/S0016-5085(15)32435-5","volume":"148","author":"JB Honneffer","year":"2015","unstructured":"Honneffer JB, Guard BC, Steiner JM, Suchodolski JS. Untargeted metabolomics reveals disruption within bile acid, cholesterol, and tryptophan metabolic pathways in dogs with idiopathic inflammatory bowel disease. (Abstract). Gastroenterology. 2015;148(4):S715.","journal-title":"Gastroenterology"},{"issue":"6","key":"99_CR7","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/jvim.15332","volume":"32","author":"PR Giaretta","year":"2018","unstructured":"Giaretta PR, Rech RR, Guard BC, Blake AB, Blick AK, Steiner JM, et al. Comparison of intestinal expression of the apical sodium-dependent bile acid transporter between dogs with and without chronic inflammatory enteropathy. J Vet Intern Med. 2018;32(6):1918\u201326.","journal-title":"J Vet Intern Med"},{"key":"99_CR8","doi-asserted-by":"publisher","unstructured":"Blake AB, Guard BC, Honneffer JB, Lidbury JA, Steiner JM, Suchodolski JS. Altered microbiota, fecal lactate, and fecal bile acids in dogs with gastrointestinal disease. PLoS One. 2019:14(10). https:\/\/doi.org\/10.1371\/journal.pone.0224454.","DOI":"10.1371\/journal.pone.0224454"},{"issue":"3","key":"99_CR9","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/jvim.15493","volume":"33","author":"BC Guard","year":"2019","unstructured":"Guard BC, Honneffer JB, Jergens AE, Jonika MM, Toresson L, Lawrence YA, et al. Longitudinal assessment of microbial dysbiosis, fecal unconjugated bile acid concentrations, and disease activity in dogs with steroid-responsive chronic inflammatory enteropathy. J Vet Intern Med. 2019;33(3):1295\u2013305.","journal-title":"J Vet Intern Med"},{"key":"99_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3389\/fvets.2020.00192","volume":"7","author":"J Chaitman","year":"2020","unstructured":"Chaitman J, Ziese AL, Pilla R, Minamoto Y, Blake AB, Guard BC, et al. Fecal microbial and metabolic profiles in dogs with acute diarrhea receiving either fecal microbiota transplantation or Oral metronidazole. Front Vet Sci. 2020;7:192. https:\/\/doi.org\/10.3389\/fvets.2020.00192.","journal-title":"Front Vet Sci"},{"issue":"6","key":"99_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.5326\/0400437","volume":"40","author":"AE Jergens","year":"2004","unstructured":"Jergens AE. Clinical assessment of disease activity for canine inflammatory bowel disease. J Am Anim Hosp Assoc. 2004;40(6):437\u201345.","journal-title":"J Am Anim Hosp Assoc"},{"key":"99_CR12","unstructured":"The WALTHAM\u2122 Faeces Scoring System Available at: https:\/\/www.waltham.com\/sites\/g\/files\/jydpyr1046\/files\/2020-05\/waltham-scoring.pdf. Accessed 12 Oct 2020."},{"issue":"4","key":"99_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/gutjnl-2012-302578","volume":"62","author":"H Duboc","year":"2013","unstructured":"Duboc H, Rajca S, Rainteau D, Benarous D, Maubert MA, Quervain E, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013;62(4):531\u20139.","journal-title":"Gut."},{"issue":"1","key":"99_CR14","doi-asserted-by":"publisher","first-page":"e000163","DOI":"10.1136\/vetreco-2015-000163","volume":"3","author":"AC Kent","year":"2016","unstructured":"Kent AC, Cross G, Taylor DR, Sherwood RA, Watson PJ. Measurement of serum 7alpha-hydroxy-4-cholesten-3-one as a marker of bile acid malabsorption in dogs with chronic diarrhoea: a pilot study. Vet Rec Open. 2016;3(1):e000163 eCollection 2016.","journal-title":"Vet Rec Open"},{"issue":"7","key":"99_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1748-5827.2004.tb00245.x","volume":"45","author":"M Craven","year":"2004","unstructured":"Craven M, Simpson JW, Ridyard AE, Chandler ML. Canine inflammatory bowel disease: retrospective analysis of diagnosis and outcome in 80 cases (1995-2002). J Small Anim Pract. 2004;45(7):336.","journal-title":"J Small Anim Pract"},{"issue":"4","key":"99_CR16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1939-1676.2007.tb03011.x","volume":"21","author":"K Allenspach","year":"2007","unstructured":"Allenspach K, Wieland B, Grone A, Gaschen F. Chronic enteropathies in dogs: evaluation of risk factors for negative outcome. J Vet Intern Med. 2007;21(4):700\u20138.","journal-title":"J Vet Intern Med"},{"issue":"2\u20134","key":"99_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.vetimm.2009.08.014","volume":"133","author":"N Luckschander","year":"2010","unstructured":"Luckschander N, Hall JA, Gaschen F, Forster U, Wenzlow N, Hermann P, et al. Activation of nuclear factor-kappaB in dogs with chronic enteropathies. Vet Immunol Immunopathol. 2010;133(2\u20134):228\u201336.","journal-title":"Vet Immunol Immunopathol"},{"issue":"12","key":"99_CR18","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.2460\/ajvr.73.12.1900","volume":"73","author":"RM Heilmann","year":"2012","unstructured":"Heilmann RM, Jergens AE, Ackermann MR, Barr JW, Suchodolski JS, Steiner JM. Serum calprotectin concentrations in dogs with idiopathic inflammatory bowel disease. Am J Vet Res. 2012;73(12):1900\u20137.","journal-title":"Am J Vet Res"},{"issue":"1","key":"99_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2460\/ajvr.74.1.78","volume":"74","author":"M Pietra","year":"2013","unstructured":"Pietra M, Fracassi F, Diana A, Gazzotti T, Bettini G, Peli A, et al. Plasma concentrations and therapeutic effects of budesonide in dogs with inflammatory bowel disease. Am J Vet Res. 2013;74(1):78\u201383.","journal-title":"Am J Vet Res"},{"issue":"3\u20134","key":"99_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.vetimm.2014.08.003","volume":"161","author":"RM Heilmann","year":"2014","unstructured":"Heilmann RM, Otoni CC, Jergens AE, Grutzner N, Suchodolski JS, Steiner JM. Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease. Vet Immunol Immunopathol. 2014;161(3\u20134):184\u201392.","journal-title":"Vet Immunol Immunopathol"},{"key":"99_CR21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.tvjl.2016.03.001","volume":"215","author":"RM Heilmann","year":"2016","unstructured":"Heilmann RM, Volkmann M, Otoni CC, Grutzner N, Kohn B, Jergens AE, et al. Fecal S100A12 concentration predicts a lack of response to treatment in dogs affected with chronic enteropathy. Vet J. 2016;215:96\u2013100.","journal-title":"Vet J"},{"issue":"2","key":"99_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/jvim.15065","volume":"32","author":"RM Heilmann","year":"2018","unstructured":"Heilmann RM, Berghoff N, Mansell J, Grutzner N, Parnell NK, Gurtner C, et al. Association of fecal calprotectin concentrations with disease severity, response to treatment, and other biomarkers in dogs with chronic inflammatory enteropathies. J Vet Intern Med. 2018;32(2):679\u201392.","journal-title":"J Vet Intern Med"},{"issue":"3","key":"99_CR23","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/jvim.15123","volume":"32","author":"CC Otoni","year":"2018","unstructured":"Otoni CC, Heilmann RM, Garcia-Sancho M, Sainz A, Ackermann MR, Suchodolski JS, et al. Serologic and fecal markers to predict response to induction therapy in dogs with idiopathic inflammatory bowel disease. J Vet Intern Med. 2018;32(3):999\u20131008.","journal-title":"J Vet Intern Med"},{"issue":"8","key":"99_CR24","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/apt.13570","volume":"43","author":"N Mottacki","year":"2016","unstructured":"Mottacki N, Simren M, Bajor A. Review article: bile acid diarrhoea - pathogenesis, diagnosis and management. Aliment Pharmacol Ther. 2016;43(8):884\u201398.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"99_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/femsec\/x136","volume":"93","author":"MK AlShawaqfeh","year":"2017","unstructured":"AlShawaqfeh MK, Wajid B, Minamoto Y, Markel M, Lidbury JA, Steiner JM, et al. A dysbiosis index to assess microbial changes in fecal samples of dogs with chronic inflammatory enteropathy. FEMS Microbiol Ecol. 2017;93(11):10. https:\/\/doi.org\/10.1093\/femsec\/x136.","journal-title":"FEMS Microbiol Ecol"},{"issue":"1 Pt 1","key":"99_CR26","first-page":"G197","volume":"273","author":"MJ Nowicki","year":"1997","unstructured":"Nowicki MJ, Shneider BL, Paul JM, Heubi JE. Glucocorticoids upregulate taurocholate transport by ileal brush-border membrane. Am J Phys. 1997;273(1 Pt 1):G197\u2013203.","journal-title":"Am J Phys"},{"issue":"1","key":"99_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/gut.53.1.78","volume":"53","author":"D Jung","year":"2004","unstructured":"Jung D, Fantin AC, Scheurer U, Fried M, Kullak-Ublick GA. Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut. 2004;53(1):78\u201384.","journal-title":"Gut."},{"key":"99_CR28","first-page":"82","volume-title":"BSAVA Small Animal Formulary","year":"2011","unstructured":"Ramsey I, editor. BSAVA Small Animal Formulary. 7th ed. Quedgeley, Gloucester: British Small Animal Veterinary Association; 2011. p. 82\u20133.","edition":"7"},{"issue":"6","key":"99_CR29","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/toxins5061051","volume":"5","author":"KA Rankin","year":"2013","unstructured":"Rankin KA, Alroy KA, Kudela RM, Oates SC, Murray MJ, Miller MA. Treatment of cyanobacterial (microcystin) toxicosis using oral cholestyramine: case report of a dog from Montana. Toxins. 2013;5(6):1051\u201363.","journal-title":"Toxins."},{"issue":"1","key":"99_CR30","first-page":"295","volume":"238","author":"TW Guentert","year":"1986","unstructured":"Guentert TW, Schmitt M, Defoin R. Acceleration of the elimination of tenoxicam by cholestyramine in the dog. J Pharmacol Exp Ther. 1986;238(1):295\u2013301.","journal-title":"J Pharmacol Exp Ther"},{"key":"99_CR31","unstructured":"Plumb\u2019s Veterinary Drugs. Available at: http:\/\/www.plumbsveterinarydrugs.com.libproxy.helsinki.fi\/#!\/monograph\/LIZ2iyvCBC. Accessed 12 Oct 2020."},{"issue":"3","key":"99_CR32","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1093\/jas\/sky437","volume":"97","author":"C Alexander","year":"2019","unstructured":"Alexander C, Guard BC, Suchodolski JS, Swanson KS. Cholestyramine decreases apparent total tract macronutrient digestibility and alters fecal characteristics and metabolites of healthy adult dogs. J Anim Sci. 2019;97(3):1020\u20136.","journal-title":"J Anim Sci"},{"key":"99_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/2050-6511-15-42","volume":"15","author":"R Singhal","year":"2014","unstructured":"Singhal R, Harrill AH, Menguy-Vacheron F, Jayyosi Z, Benzerdjeb H, Watkins PB. Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine. BMC Pharmacol Toxicol. 2014;15:42.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"99_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.7326\/0003-4819-72-1-95","volume":"72","author":"L Gross","year":"1970","unstructured":"Gross L, Brotman M. Hypoprothrombinemia and hemorrhage associated with cholestyramine therapy. Ann Intern Med. 1970;72(1):95\u20136.","journal-title":"Ann Intern Med"},{"issue":"1","key":"99_CR35","first-page":"27","volume":"105","author":"R Acuna","year":"1977","unstructured":"Acuna R, Gonzalez CM. Hypoprothrombinemia and bleeding associated to treatment with cholestyramine (author's transl). Rev Med Chil. 1977;105(1):27\u20138.","journal-title":"Rev Med Chil"},{"issue":"6","key":"99_CR36","first-page":"609","volume":"134","author":"AM Shojania","year":"1986","unstructured":"Shojania AM, Grewar D. Hypoprothrombinemic hemorrhage due to cholestyramine therapy. CMAJ. 1986;134(6):609\u201310.","journal-title":"CMAJ"},{"issue":"1","key":"99_CR37","first-page":"19","volume":"61","author":"K Vroonhof","year":"2003","unstructured":"Vroonhof K, van Rijn HJ, van Hattum J. Vitamin K deficiency and bleeding after long-term use of cholestyramine. Neth J Med. 2003;61(1):19\u201321.","journal-title":"Neth J Med"},{"key":"99_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3181\/00379727-115-28845","volume":"115","author":"HJ Robinson","year":"1964","unstructured":"Robinson HJ, Kelley KL, Lehman EG. Effect of Cholestyramine, a bile acid binding polymer, on vitamin K1 absorption in dogs. Proc Soc Exp Biol Med. 1964;115:112\u20135.","journal-title":"Proc Soc Exp Biol Med"},{"issue":"5","key":"99_CR39","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1053\/j.gastro.2018.11.069","volume":"156","author":"P Vijayvargiya","year":"2019","unstructured":"Vijayvargiya P, Camilleri M. Current practice in the diagnosis of bile acid diarrhea. Gastroenterology. 2019;156(5):1233\u20138.","journal-title":"Gastroenterology"},{"issue":"1","key":"99_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cgh.2019.10.031","volume":"18","author":"LR Schiller","year":"2020","unstructured":"Schiller LR. Good news about BAD. Clin Gastroenterol Hepatol. 2020;18(1):45\u20137.","journal-title":"Clin Gastroenterol Hepatol"}],"updated-by":[{"DOI":"10.1186\/s40575-021-00102-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000}}],"container-title":["Canine Medicine and Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40575-021-00099-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40575-021-00099-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40575-021-00099-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T16:22:04Z","timestamp":1627662124000},"score":1,"resource":{"primary":{"URL":"https:\/\/cgejournal.biomedcentral.com\/articles\/10.1186\/s40575-021-00099-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["99"],"URL":"https:\/\/doi.org\/10.1186\/s40575-021-00099-x","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s40575-021-00102-5","asserted-by":"object"}]},"ISSN":["2662-9380"],"issn-type":[{"value":"2662-9380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"15 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40575-021-00102-5","URL":"https:\/\/doi.org\/10.1186\/s40575-021-00102-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The owners of both dogs agreed to publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JMS and JSS work for the Gastrointestinal Laboratory at Texas A&M University that performs measurement of the dysbiosis index on a fee for service basis. LT has no financial or personal relationships that could inappropriately influence or bias the content of the paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}